Experience with linezolid therapy in children with osteoarticular infections

Chih Jung Chen, Cheng Hsun Chiu, Tzou Yien Lin, Zhon Liau Lee, Wen E. Yang, Yhu Chering Huang

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

BACKGROUND: The excellent oral bioavailability and the Gram-positive antimicrobial spectrum make linezolid an attractive antibiotic for treatment of osteoarticular infections. The clinical efficacy of this drug has not been previously evaluated for Gram-positive osteoarticular infections in children. METHODS: Between July 2003 and June 2006, 13 children who received a linezolid-containing regimen for osteoarticular infections were identified from a hospital pharmacy database. The medical records were reviewed and outcomes with regard to clinical efficacy and safety were analyzed. RESULTS: Eight (61.5%) children were male. Ages ranged from 3 months to 14 years. Nine previously healthy children had acute hematogenous osteoarticular infections involving the pelvis (n = 1) or lower limbs (n = 8). The remaining 4 children had postoperative infections of sternal wounds (n = 2) and fractured lower limbs (n = 2). Causative pathogens included methicillin-resistant Staphylococcus aureus in 11 children, methicillin-susceptible S. aureus in one, and Enterococcus faecium and coagulase-negative staphylococci in one. Surgical debridement was attempted in 9 children and effective antistaphylococcal antibiotics were used in all 13 patients for a median duration of 23 days (range, 5-41 days) before the use of linezolid. Linezolid was administered orally to 10 children as step-down therapy and by the parenteral followed by oral route to 3 children who were intolerant of glycopeptide for a median duration of 20 days (range, 9-36 days). Eleven of the 13 children were cured after management. Two children developed anemia during linezolid therapy. There was no premature cessation of linezolid because of severe adverse effects. CONCLUSION: Linezolid appears to be useful and well tolerated in step-down therapy or compassionate use for pediatric Gram-positive orthopedic infections. A well-designed prospective comparative study is needed to confirm this observation.

Original languageEnglish
Pages (from-to)985-988
Number of pages4
JournalPediatric Infectious Disease Journal
Volume26
Issue number11
DOIs
Publication statusPublished - Nov 2007
Externally publishedYes

Fingerprint

Linezolid
Infection
Therapeutics
Lower Extremity
Compassionate Use Trials
Anti-Bacterial Agents

Keywords

  • Children
  • Community-acquired infections
  • Linezolid
  • Methicillin-resistant Staphylococcus aureus
  • Osteoarticular infections

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)

Cite this

Experience with linezolid therapy in children with osteoarticular infections. / Chen, Chih Jung; Chiu, Cheng Hsun; Lin, Tzou Yien; Lee, Zhon Liau; Yang, Wen E.; Huang, Yhu Chering.

In: Pediatric Infectious Disease Journal, Vol. 26, No. 11, 11.2007, p. 985-988.

Research output: Contribution to journalArticle

Chen, Chih Jung ; Chiu, Cheng Hsun ; Lin, Tzou Yien ; Lee, Zhon Liau ; Yang, Wen E. ; Huang, Yhu Chering. / Experience with linezolid therapy in children with osteoarticular infections. In: Pediatric Infectious Disease Journal. 2007 ; Vol. 26, No. 11. pp. 985-988.
@article{4f0c6df7919845e28e96c32d0c4e5339,
title = "Experience with linezolid therapy in children with osteoarticular infections",
abstract = "BACKGROUND: The excellent oral bioavailability and the Gram-positive antimicrobial spectrum make linezolid an attractive antibiotic for treatment of osteoarticular infections. The clinical efficacy of this drug has not been previously evaluated for Gram-positive osteoarticular infections in children. METHODS: Between July 2003 and June 2006, 13 children who received a linezolid-containing regimen for osteoarticular infections were identified from a hospital pharmacy database. The medical records were reviewed and outcomes with regard to clinical efficacy and safety were analyzed. RESULTS: Eight (61.5{\%}) children were male. Ages ranged from 3 months to 14 years. Nine previously healthy children had acute hematogenous osteoarticular infections involving the pelvis (n = 1) or lower limbs (n = 8). The remaining 4 children had postoperative infections of sternal wounds (n = 2) and fractured lower limbs (n = 2). Causative pathogens included methicillin-resistant Staphylococcus aureus in 11 children, methicillin-susceptible S. aureus in one, and Enterococcus faecium and coagulase-negative staphylococci in one. Surgical debridement was attempted in 9 children and effective antistaphylococcal antibiotics were used in all 13 patients for a median duration of 23 days (range, 5-41 days) before the use of linezolid. Linezolid was administered orally to 10 children as step-down therapy and by the parenteral followed by oral route to 3 children who were intolerant of glycopeptide for a median duration of 20 days (range, 9-36 days). Eleven of the 13 children were cured after management. Two children developed anemia during linezolid therapy. There was no premature cessation of linezolid because of severe adverse effects. CONCLUSION: Linezolid appears to be useful and well tolerated in step-down therapy or compassionate use for pediatric Gram-positive orthopedic infections. A well-designed prospective comparative study is needed to confirm this observation.",
keywords = "Children, Community-acquired infections, Linezolid, Methicillin-resistant Staphylococcus aureus, Osteoarticular infections",
author = "Chen, {Chih Jung} and Chiu, {Cheng Hsun} and Lin, {Tzou Yien} and Lee, {Zhon Liau} and Yang, {Wen E.} and Huang, {Yhu Chering}",
year = "2007",
month = "11",
doi = "10.1097/INF.0b013e31812e62dc",
language = "English",
volume = "26",
pages = "985--988",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Experience with linezolid therapy in children with osteoarticular infections

AU - Chen, Chih Jung

AU - Chiu, Cheng Hsun

AU - Lin, Tzou Yien

AU - Lee, Zhon Liau

AU - Yang, Wen E.

AU - Huang, Yhu Chering

PY - 2007/11

Y1 - 2007/11

N2 - BACKGROUND: The excellent oral bioavailability and the Gram-positive antimicrobial spectrum make linezolid an attractive antibiotic for treatment of osteoarticular infections. The clinical efficacy of this drug has not been previously evaluated for Gram-positive osteoarticular infections in children. METHODS: Between July 2003 and June 2006, 13 children who received a linezolid-containing regimen for osteoarticular infections were identified from a hospital pharmacy database. The medical records were reviewed and outcomes with regard to clinical efficacy and safety were analyzed. RESULTS: Eight (61.5%) children were male. Ages ranged from 3 months to 14 years. Nine previously healthy children had acute hematogenous osteoarticular infections involving the pelvis (n = 1) or lower limbs (n = 8). The remaining 4 children had postoperative infections of sternal wounds (n = 2) and fractured lower limbs (n = 2). Causative pathogens included methicillin-resistant Staphylococcus aureus in 11 children, methicillin-susceptible S. aureus in one, and Enterococcus faecium and coagulase-negative staphylococci in one. Surgical debridement was attempted in 9 children and effective antistaphylococcal antibiotics were used in all 13 patients for a median duration of 23 days (range, 5-41 days) before the use of linezolid. Linezolid was administered orally to 10 children as step-down therapy and by the parenteral followed by oral route to 3 children who were intolerant of glycopeptide for a median duration of 20 days (range, 9-36 days). Eleven of the 13 children were cured after management. Two children developed anemia during linezolid therapy. There was no premature cessation of linezolid because of severe adverse effects. CONCLUSION: Linezolid appears to be useful and well tolerated in step-down therapy or compassionate use for pediatric Gram-positive orthopedic infections. A well-designed prospective comparative study is needed to confirm this observation.

AB - BACKGROUND: The excellent oral bioavailability and the Gram-positive antimicrobial spectrum make linezolid an attractive antibiotic for treatment of osteoarticular infections. The clinical efficacy of this drug has not been previously evaluated for Gram-positive osteoarticular infections in children. METHODS: Between July 2003 and June 2006, 13 children who received a linezolid-containing regimen for osteoarticular infections were identified from a hospital pharmacy database. The medical records were reviewed and outcomes with regard to clinical efficacy and safety were analyzed. RESULTS: Eight (61.5%) children were male. Ages ranged from 3 months to 14 years. Nine previously healthy children had acute hematogenous osteoarticular infections involving the pelvis (n = 1) or lower limbs (n = 8). The remaining 4 children had postoperative infections of sternal wounds (n = 2) and fractured lower limbs (n = 2). Causative pathogens included methicillin-resistant Staphylococcus aureus in 11 children, methicillin-susceptible S. aureus in one, and Enterococcus faecium and coagulase-negative staphylococci in one. Surgical debridement was attempted in 9 children and effective antistaphylococcal antibiotics were used in all 13 patients for a median duration of 23 days (range, 5-41 days) before the use of linezolid. Linezolid was administered orally to 10 children as step-down therapy and by the parenteral followed by oral route to 3 children who were intolerant of glycopeptide for a median duration of 20 days (range, 9-36 days). Eleven of the 13 children were cured after management. Two children developed anemia during linezolid therapy. There was no premature cessation of linezolid because of severe adverse effects. CONCLUSION: Linezolid appears to be useful and well tolerated in step-down therapy or compassionate use for pediatric Gram-positive orthopedic infections. A well-designed prospective comparative study is needed to confirm this observation.

KW - Children

KW - Community-acquired infections

KW - Linezolid

KW - Methicillin-resistant Staphylococcus aureus

KW - Osteoarticular infections

UR - http://www.scopus.com/inward/record.url?scp=37349008467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349008467&partnerID=8YFLogxK

U2 - 10.1097/INF.0b013e31812e62dc

DO - 10.1097/INF.0b013e31812e62dc

M3 - Article

C2 - 17984803

AN - SCOPUS:37349008467

VL - 26

SP - 985

EP - 988

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 11

ER -